Treatment of disseminated non-seminomatous testicular cancer: the European experience (Q33788904)

29 July 2017

1 reference

title

Treatment of disseminated non-seminomatous testicular cancer: the European experience (English)

1 reference

29 July 2017

1 reference

de Wit R

1

1 reference

29 July 2017

1 December 1999

1 reference

Journal of Surgical Oncology

29 July 2017

1 reference

29 July 2017

17

1 reference

29 July 2017

4

1 reference

29 July 2017

250-256

1 reference

Treatment of testicular cancer: a new and improved model

29 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Ca

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Bleomycin in germ cell tumor therapy: not all regimens are created equal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199912%2917%3A4%3C250%3A%3AAID-SSU5%3E3.0.CO%3B2-M

10.1002/(SICI)1098-2388(199912)17:4<250::AID-SSU5>3.0.CO;2-M

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10588853